Education
About Us
Working with TipRanks
Follow Us
LakeShore Biopharma (LSB)
NASDAQ:LSB
Top Page
LakeShore Biopharma
(NASDAQ:LSB)
38Underperform
LakeShore Biopharma (LSB) vs. S&P 500 (SPY)
Market Cap
$40.07M
Dividend YieldN/A
Average Volume (3M)6.83K
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees758
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,080,751
10 Day Avg. Volume5,387
30 Day Avg. Volume6,833
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.51
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
LakeShore Biopharma Business Overview & Revenue Model
Company DescriptionLakeShore Biopharma (LSB) is a biotechnology company specializing in the development and commercialization of innovative therapeutics and diagnostic solutions. Operating in the healthcare and life sciences sectors, LSB focuses on addressing unmet medical needs through cutting-edge research and development. The company's core products include a pipeline of proprietary drug candidates and advanced diagnostic tools designed to enhance patient care and improve clinical outcomes.
How the Company Makes MoneyLakeShore Biopharma generates revenue through a combination of product sales, licensing agreements, and strategic partnerships. Key revenue streams include sales of its proprietary therapeutics and diagnostic solutions to healthcare providers, hospitals, and research institutions. LSB also licenses its technology and compounds to other pharmaceutical companies, providing an additional source of income through upfront payments, milestone payments, and royalties. Strategic partnerships with academic institutions and industry leaders further bolster LSB's earnings by facilitating co-development projects and expanding market reach.
LakeShore Biopharma Financial Statement Overview
Summary
LakeShore Biopharma is facing significant financial challenges, with declining revenues, substantial losses, and negative cash flows. The income statement reflects a revenue decline and negative margins, indicating operational difficulties. The balance sheet shows moderate leverage but declining equity, suggesting potential instability. Cash flow issues further highlight liquidity concerns needing urgent attention.Income Statement
LakeShore Biopharma has experienced declining revenue over the past year, with a notable decrease in total revenue from $687 million to $573 million, reflecting an annual revenue growth rate of -16.56%. The company also reports negative margins, with a net profit margin of -75.58% and an EBIT margin of -77.75% for the latest year, indicating significant losses relative to revenue. These factors highlight a challenging financial situation, with substantial operational losses.30
Negative
Balance Sheet
The company's balance sheet reveals a debt-to-equity ratio of 0.73, which suggests moderate leverage but potentially higher risk given the industry's volatility. Stockholders' equity decreased from $728 million to $585 million, highlighting a decline in equity value. The equity ratio stands at 38.67%, indicating that a fair portion of the company's assets is financed through equity, but the decline in equity suggests potential instability.40
Negative
Cash Flow
Cash flow analysis shows a negative free cash flow growth rate, with free cash flow deteriorating from -$239 million to -$339 million. The operating cash flow to net income ratio is negative, reflecting cash flow challenges in line with operational losses. These patterns point to liquidity concerns and the need for improved cash flow management to support operations.35
Negative
| Breakdown | ||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 547.92M | 573.42M | 687.20M | 502.95M | 257.02M | Gross Profit |
| 439.68M | 455.73M | 533.84M | 385.88M | 197.36M | EBIT |
| -340.91M | -445.83M | -139.38M | -549.18K | -125.85M | EBITDA |
| -288.58M | -368.66M | -76.80M | -67.20M | -116.78M | Net Income Common Stockholders |
| -365.75M | -433.46M | -145.48M | -545.73K | -191.83M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 222.66M | 246.35M | 370.11M | 885.20K | 390.46M | Total Assets |
| 1.51B | 1.51B | 1.72B | 201.03M | 91.37K | Total Debt |
| 558.20M | 424.46M | 498.63M | 380.59M | 5.01K | Net Debt |
| 335.54M | 178.11M | 128.52M | 379.70M | -390.45M | Total Liabilities |
| 1.01B | 927.82M | 991.30M | 20.35M | 70.01K | Stockholders Equity |
| 474.60M | 585.21M | 728.45M | 180.68M | 21.36K |
| Cash Flow | Free Cash Flow | |||
| 0.00 | -339.48M | -239.52M | -299.55M | -351.49M | Operating Cash Flow |
| 0.00 | -295.23M | -182.47M | -613.23K | -246.61M | Investing Cash Flow |
| 0.00 | -44.25M | -56.98M | -200.00M | -104.24M | Financing Cash Flow |
| 0.00 | 205.26M | 317.45M | 201.50M | 739.26M |
LakeShore Biopharma Technical Analysis
Negative
2.10
Price Trends
2.59
Negative
2.67
Negative
4.23
Negative
Market Momentum
-0.14
Positive
32.77
Neutral
33.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSB, the sentiment is Negative. The current price of 2.1 is below the 20-day moving average (MA) of 2.25, below the 50-day MA of 2.59, and below the 200-day MA of 4.23, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 32.77 is Neutral, neither overbought nor oversold. The STOCH value of 33.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LSB.
LakeShore Biopharma Risk Analysis
LakeShore Biopharma disclosed 100 risk factors in its most recent earnings report. LakeShore Biopharma reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LakeShore Biopharma Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $78.51B | 19.43 | 15.95% | 0.12% | 8.27% | 10.35% | |
75 Outperform | $142.50B | 306.43 | 2.28% | 2.63% | 6.16% | -91.54% | |
75 Outperform | $171.31B | 43.30 | 67.55% | 2.79% | 18.64% | -39.39% | |
69 Neutral | $21.03B | 12.85 | 10.36% | ― | -1.60% | 39.71% | |
64 Neutral | $128.40B | ― | -3.15% | ― | 11.64% | -114.72% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
38 Underperform | $40.07M | ― | -74.07% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
LSB
LakeShore Biopharma
1.85
-4.91
-72.63%
AMGN
Amgen
318.89
50.53
18.83%
BIIB
Biogen
143.66
-83.70
-36.81%
GILD
Gilead Sciences
114.43
42.30
58.64%
REGN
Regeneron
718.16
-251.16
-25.91%
VRTX
Vertex Pharmaceuticals
488.34
75.89
18.40%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.